Incorporating preauthorization into antimicrobial stewardship pharmacist workflow reduces Clostridioides difficile and gastrointestinal panel testing. (3rd October 2020)

• Record Type: Journal Article
• Authors: Tran, Nikki N.; Mills, John P.; Zimmerman, Christopher; Gandhi, Tejal N.; Tribble, Alison C.; Petty, Lindsay A.; Nagel, Jerod; Brancaccio, Adamo; Scappaticci, Gianni; Patel, Twisha; Dillman, Nicholas O.; Regal, Randolph; Klein, Kristin C.; Washer, Laraine; Marshall, Vincent D.; Sweeney, Jennifer; Rao, Krishna; Eschenauer, Gregory A.
• Is Part Of: Infection control and hospital epidemiology. Volume 41:Number 10(2020)
• Page Start: 1136
• Page End: 1141
• Publication Date: 2020-10-03
• Subjects: Nosocomial infections -- Epidemiology -- Periodicals; Health facilities -- Sanitation -- Periodicals; Hospital buildings -- Sanitation -- Periodicals; Cross Infection -- Periodicals; Epidemiology -- Periodicals; Hospitals -- Periodicals; Infection Control -- Periodicals; 614.44
• DOI: 10.1017/ice.2020.236
• Languages: English
• ISSNs: 0899-823X

Abstract

Abstract: Objective: To evaluate whether incorporating mandatory prior authorization for Clostridioides difficile testing into antimicrobial stewardship pharmacist workflow could reduce testing in patients with alternative etiologies for diarrhea. Design: Single center, quasi-experimental before-and-after study. Setting: Tertiary-care, academic medical center in Ann Arbor, Michigan. Patients: Adult and pediatric patients admitted between September 11, 2019 and December 10, 2019 were included if they had an order placed for 1 of the following: (1) C. difficile enzyme immunoassay (EIA) in patients hospitalized >72 hours and received laxatives, oral contrast, or initiated tube feeds within the prior 48 hours, (2) repeat molecular multiplex gastrointestinal pathogen panel (GIPAN) testing, or (3) GIPAN testing in patients hospitalized >72 hours. Intervention: A best-practice alert prompting prior authorization by the antimicrobial stewardship program (ASP) for EIA or GIPAN testing was implemented. Approval required the provider to page the ASP pharmacist and discuss rationale for testing. The provider could not proceed with the order if ASP approval was not obtained. Results: An average of 2.5 requests per day were received over the 3-month intervention period. The weekly rate of EIA and GIPAN orders per 1, 000 patient days decreased significantly from 6.05 ± 0.94 to 4.87 ± 0.78 (IRR, 0.72; 95% CI, 0.56–0.93; P = .010) and from 1.72 ± 0.37 to 0.89 ± 0.29 (IRR, 0.53; 95% CI, 0.37–0.77; P = .001), respectively. Conclusions: We identified an efficient, effective C. difficile and GIPAN diagnostic stewardship approval model.